4-methyl-2-(4-nitrophenyl)pyridine | 20807-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-methyl-2-(4-nitrophenyl)pyridine
• CAS: 20807-64-1
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: XBCIKFKMGIMIPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methyl-2-(4-nitrophenyl)pyridine 在 palladium on activated charcoal 盐酸 、 氯化亚砜 、 氢气 、 双氧水 、 sodium acetate 、 硫酸二甲酯 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.5h， 生成 ethyl 6-(4-aminophenyl)-4-methyl-2-pyridinecarboxylate hydrochloride
  参考文献：
  名称：

  Antiallergic agents. 2. N-(1H-Tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides

  摘要：

  A new series of N-(1H-tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides was prepared to determine the effects of substituents on the benzene and pyridine rings on antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) assay after oral administration. One member of this series, N-(1H-tetrazol-5-yl)-4-methyl-6-[4-(methylamino)-phenyl]-2- pyridinecarboxamide (231), has an ED50 value of 0.8 mg/kg po and is 85 times more potent than disodium cromoglycate (DSCG) on intravenous administration. Further evaluation of 231 as a clinically useful antiallergic agent is in progress.

  DOI：

  10.1021/jm00364a026
• 作为产物：
  描述：

  4-Methyl-2-phenylpyridine nitrate 、 4-甲基-2-苯基吡啶 、 硝酸 、 硫酸 、 氨 在 乙醇 作用下， 以 ice water 为溶剂， 反应 0.5h， 以to give 4-methyl-2-(4-nitrophenyl)pyridine (13.3 g)的产率得到4-methyl-2-(4-nitrophenyl)pyridine
  参考文献：
  名称：

  Pyridinecarboxamide derivatives and process for the preparation thereof

  摘要：

  该式的N-(5-四唑基)-6-苯基-2-吡啶羧酰胺衍生物：##STR1## 其中R是氢，卤素，低烷基或低烷氧基，苯环A是具有从氨基，一种单一（低）烷基氨基，一种二（低）烷基氨基或一种低脂肪酰基氨基中选择的取代基的苯基，以及其药学上可接受的盐，以及其制备方法。所述的吡啶羧酰胺衍生物即使通过口服也具有出色的抗过敏活性，并且可用作抗过敏药物。

  公开号：

  US04332809A1

文献信息

• Novel pyridinecarboxamide derivatives, a process for the preparation thereof, the use of said derivatives and a pharmaceutical composition containing same
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0034349A2

  公开（公告）日：1981-08-26

  Novel pyridinecarboxamide derivatives of the formula wherein R is hydrogen, a halogen, a lower alkyl or a lower alkoxy, and the phenyl ring A is a phenyl having a substituent selected from the group consisting of amino, a mono-(lower)alkylamino, a di(lower)alkylamino, or a lower aliphatic acylamino, and a pharmaceutically acceptable salt thereof, and process for the preparation thereof. Said pyridinecarboxamide derivatives have excellent anti-allergic activities even by oral administration and in form of pharmaceutical compositions are useful as an anti-allergic medicine.

  式中的新型吡啶甲酰胺衍生物 其中 R 是氢、卤素、低级烷基或低级烷氧基，苯基环 A 是具有选自氨基、一（低级）烷基氨基、二（低级）烷基氨基或低级脂族酰氨基的取代基的苯基，及其药学上可接受的盐，以及其制备工艺。所述吡啶甲酰胺衍生物即使口服也具有极佳的抗过敏活性，以药物组合物的形式用作抗过敏药物非常有用。
• US4332809A
  申请人：——

  公开号：US4332809A

  公开（公告）日：1982-06-01
• Pyridinecarboxamide derivatives and process for the preparation thereof
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04332809A1

  公开（公告）日：1982-06-01

  N-(5-Tetrazolyl)-6-phenyl-2-pyridinecarboxamide derivatives of the formula: ##STR1## wherein R is hydrogen, a halogen, a lower alkyl or a lower alkoxy, and the phenyl ring A is a phenyl having a substituent selected from the group consisting of amino, a mono(lower)alkylamino, a di(lower)alkylamino, or a lower aliphatic acylamino, and a pharmaceutically acceptable salt thereof, and process for the preparation thereof. Said pyridinecarboxamide derivatives have excellent anti-allergic activities even by oral administration and are useful as an anti-allergic medicine.

  N-(5-四唑基)-6-苯基-2-吡啶甲酰胺类化合物的结构式为：##STR1## 其中 R 为氢、卤素、低烷基或低烷氧基，苯环 A 为苯基，并具有从氨基、一元(低)烷基氨基、二元(低)烷基氨基，或低脂肪酰氨基中选择的取代基，以及其药学上可接受的盐，以及其制备方法。所述的吡啶甲酰胺类衍生物即使通过口服也具有出色的抗过敏活性，并可用作抗过敏药物。
• Antiallergic agents. 2. N-(1H-Tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides
  作者：Yasushi Honma、Kuniyuki Oda、Tomiki Hashiyama、Kyoji Hanamoto、Hideo Nakai、Hirozumi Inoue、Akihiko Ishida、Mikio Takeda、Yasutoshi Ono、Kei Tsuzurahara

  DOI：10.1021/jm00364a026

  日期：1983.10

  A new series of N-(1H-tetrazol-5-yl)-6-phenyl-2-pyridinecarboxamides was prepared to determine the effects of substituents on the benzene and pyridine rings on antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) assay after oral administration. One member of this series, N-(1H-tetrazol-5-yl)-4-methyl-6-[4-(methylamino)-phenyl]-2- pyridinecarboxamide (231), has an ED50 value of 0.8 mg/kg po and is 85 times more potent than disodium cromoglycate (DSCG) on intravenous administration. Further evaluation of 231 as a clinically useful antiallergic agent is in progress.